You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 21, 2024

CLINICAL TRIALS PROFILE FOR LIPITOR


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for LIPITOR

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00023231 ↗ Pediatric Kidney Transplant Without Calcineurin Inhibitors Completed National Institute of Allergy and Infectious Diseases (NIAID) N/A 2001-02-01 The purpose of this study is to see the effect of using drugs other than calcineurin inhibitors to improve the rate of kidney transplant failure. Kidney transplantation can help children with end-stage kidney disease. However, it has been difficult to find treatment for donor graft rejection that does not have a lot of side effects. Researchers hope to find treatments (immunosuppressants) with fewer side effects. One approach is to avoid using calcineurin inhibitors and to try a new drug known as sirolimus instead. Another is to use steroids less often. This study will test whether using sirolimus, fewer steroid treatments, MMF, and certain antibodies will improve long-term graft survival in children receiving kidney transplants from living donors.
NCT00024531 ↗ Lipitor as a Treatment for Alzheimer's Disease Completed Pfizer Phase 2 2000-10-01 The purpose of this study is to assess the clinical benefit of Lipitor, a cholesterol-lowering drug, in the treatment of Alzheimer's disease.
NCT00024531 ↗ Lipitor as a Treatment for Alzheimer's Disease Completed Institute for the Study of Aging (ISOA) Phase 2 2000-10-01 The purpose of this study is to assess the clinical benefit of Lipitor, a cholesterol-lowering drug, in the treatment of Alzheimer's disease.
NCT00065806 ↗ Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE) Completed Laura Schanberg Phase 3 2003-09-01 The purpose of this study is: 1. To assess the efficacy of a lipid-lowering agent (atorvastatin) on the development of atherosclerosis that predisposes children with SLE to cardiovascular events in adulthood. 2. To assess the safety of intermediate-term (36 months) treatment of children and young adults with atorvastatin. 3. To further characterize the course of SLE in children and young adults, by establishing a cohort of pediatric SLE patients to be followed prospectively. 4. To establish a mechanism for conducting clinical trials in rare pediatric rheumatic diseases using the Children's Arthritis and Rheumatology Research Alliance (CARRA).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for LIPITOR

Condition Name

Condition Name for LIPITOR
Intervention Trials
Hypercholesterolemia 31
Healthy 18
Hyperlipidemia 13
Coronary Artery Disease 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for LIPITOR
Intervention Trials
Hypercholesterolemia 38
Dyslipidemias 23
Coronary Artery Disease 23
Myocardial Ischemia 22
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for LIPITOR

Trials by Country

Trials by Country for LIPITOR
Location Trials
United States 571
Japan 54
Canada 43
China 39
Italy 29
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for LIPITOR
Location Trials
Texas 31
California 30
Ohio 25
Florida 25
New York 23
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for LIPITOR

Clinical Trial Phase

Clinical Trial Phase for LIPITOR
Clinical Trial Phase Trials
Phase 4 56
Phase 3 50
Phase 2/Phase 3 3
[disabled in preview] 50
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for LIPITOR
Clinical Trial Phase Trials
Completed 160
Terminated 20
Unknown status 17
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for LIPITOR

Sponsor Name

Sponsor Name for LIPITOR
Sponsor Trials
Pfizer 25
AstraZeneca 13
Merck Sharp & Dohme Corp. 10
[disabled in preview] 9
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for LIPITOR
Sponsor Trials
Other 207
Industry 135
NIH 30
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.